Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.

Ortiz Zacarías NV, Dijkmans AC, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Kamerling IMC, Stevens J.

Pharmacol Res Perspect. 2018 Feb;6(1). doi: 10.1002/prp2.378.

2.

Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.

PMID:
29194939
3.

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerling IMC.

Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24. doi: 10.3390/antibiotics6040024. Review.

4.

[Clioquinol use for Dientamoeba fragilis infections is questionable].

van Hunsel F, van Nieuwkoop C, Stricker BHC.

Ned Tijdschr Geneeskd. 2017;161(0):D1477. Dutch.

PMID:
28880141
5.

[Fosfomycin, an old antibiotic with new possibilities].

Dijkmans AC, Kuiper SG, Burggraaf J, Mouton JW, Wilms EB, Touw DJ, Stevens J, van Nieuwkoop C, Kamerling IMC.

Ned Tijdschr Geneeskd. 2017;161(0):D973. Dutch.

PMID:
28612692
6.

Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule.

Stalenhoef JE, van der Starre WE, Vollaard AM, Steyerberg EW, Delfos NM, Leyten EMS, Koster T, Ablij HC, Van't Wout JW, van Dissel JT, van Nieuwkoop C.

BMC Infect Dis. 2017 Jun 6;17(1):400. doi: 10.1186/s12879-017-2509-3.

7.

Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.

van Nieuwkoop C, van der Starre WE, Stalenhoef JE, van Aartrijk AM, van der Reijden TJ, Vollaard AM, Delfos NM, van 't Wout JW, Blom JW, Spelt IC, Leyten EM, Koster T, Ablij HC, van der Beek MT, Knol MJ, van Dissel JT.

BMC Med. 2017 Apr 3;15(1):70. doi: 10.1186/s12916-017-0835-3.

8.

Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.

de Bruin M, Oberjé EJM, Viechtbauer W, Nobel HE, Hiligsmann M, van Nieuwkoop C, Veenstra J, Pijnappel FJ, Kroon FP, van Zonneveld L, Groeneveld PHP, van Broekhuizen M, Evers SMAA, Prins JM.

Lancet Infect Dis. 2017 Jun;17(6):595-604. doi: 10.1016/S1473-3099(16)30534-5. Epub 2017 Mar 3.

PMID:
28262598
9.

Appendicitis Presenting As Cellulitis of the Right Leg.

van Hulsteijn LT, Mieog JS, Zwartbol MH, Merkus JW, van Nieuwkoop C.

J Emerg Med. 2017 Jan;52(1):e1-e3. doi: 10.1016/j.jemermed.2016.07.008. Epub 2016 Sep 19.

PMID:
27658552
10.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study.

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355. Epub 2016 Feb 4.

PMID:
26842457
11.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
12.

Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, Reiss P; ATHENA National Observational HIV Cohort.

BMJ Open. 2016 Jan 4;6(1):e009688. doi: 10.1136/bmjopen-2015-009688.

13.

Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic Analysis.

Bezemer D, Cori A, Ratmann O, van Sighem A, Hermanides HS, Dutilh BE, Gras L, Rodrigues Faria N, van den Hengel R, Duits AJ, Reiss P, de Wolf F, Fraser C; ATHENA observational cohort.

PLoS Med. 2015 Nov 3;12(11):e1001898; discussion e1001898. doi: 10.1371/journal.pmed.1001898. eCollection 2015 Nov.

14.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

15.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
16.

Life-threatening acute lung injury after gamma butyrolactone ingestion.

van Gerwen M, Scheper H, Touw DJ, van Nieuwkoop C.

Neth J Med. 2015 Mar;73(3):133-5.

17.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

18.

Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study.

van der Starre WE, van Nieuwkoop C, Thomson U, Zijderveld-Voshart MS, Koopman JP, van der Reijden TJ, van Dissel JT, van de Vosse E.

PLoS One. 2015 Mar 25;10(3):e0121302. doi: 10.1371/journal.pone.0121302. eCollection 2015.

19.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
20.

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.

Zhang S, van Sighem A, Kesselring A, Gras L, Prins JM, Hassink E, Kauffmann R, Richter C, de Wolf F, Reiss P; ATHENA national observational HIV cohort study.

HIV Med. 2015 May;16(5):265-72. doi: 10.1111/hiv.12202. Epub 2015 Jan 21.

Supplemental Content

Loading ...
Support Center